Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.42 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.42 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.42 |
| ▸ | WDR5 | P61964 | 15/20 | 0.40 |
| ▸ | FLT3 | P36888 | 3/20 | 0.35 |
| ▸ | CFTR | P13569 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2817064 | 0.94 | CSNK2A1 (0.41) | CSNK2A1PIM3CLK4WDR5FLT3 | |
| SCHEMBL2814612 | 0.86 | CSNK2A1 (0.42) | CSNK2A1PIM3CLK4WDR5FLT3 | |
| SCHEMBL2814614 | 0.86 | CSNK2A1 (0.42) | CSNK2A1PIM3CLK4WDR5FLT3 | |
| SCHEMBL2818367 | 0.86 | CSNK2A1 (0.42) | CSNK2A1PIM3CLK4WDR5FLT3 | |
| SCHEMBL2817440 | 0.84 | CSNK2A1 (0.44) | CSNK2A1PIM3CLK4WDR5CFTR | |
| SCHEMBL2814011 | 0.83 | AR (0.43) | CSNK2A1PIM3CLK4WDR5FLT3 | |
| SCHEMBL2814015 | 0.83 | AR (0.43) | CSNK2A1PIM3CLK4WDR5FLT3 | |
| SCHEMBL2980090 | 0.82 | CFTR (0.43) | WDR5FLT3CFTR | |
| SCHEMBL2966616 | 0.79 | CFTR (0.46) | WDR5CFTR | |
| SCHEMBL2054281 | 0.79 | CFTR (0.58) | CFTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9399648-B2 | Isothiazolopyridinones useful for the treatment of (inter alia) cystic fibrosis | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-07-26 | — | — | US | claimed |
| EP-2187884-B1 | ISOTHIAZOLOPYRIDINONES USEFUL FOR THE TREATMENT OF (INTER ALIA) CYSTIC FIBROSIS | VERTEX PHARMA (US) | 2016-03-30 | — | — | EP | claimed |
| US-8802844-B2 | Isothiazolopyridinones useful for the treatment of (inter alia) cystic fibrosis | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-12 | — | — | US | claimed |
| US-20100249180-A1 | ISOTHIAZOLOPYRIDINONES USEFUL FOR THE TREATMENT OF (INTER ALIA) CYSTIC FIBROSIS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-09-30 | — | — | US | claimed |
| US-9399648-B2 | Isothiazolopyridinones useful for the treatment of (inter alia) cystic fibrosis | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-07-26 | — | — | US | disclosed |
| US-9399648-B2 | Isothiazolopyridinones useful for the treatment of (inter alia) cystic fibrosis | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-07-26 | — | — | US | disclosed |
| US-20150031720-A1 | ISOTHIAZOLOPYRIDINONES USEFUL FOR THE TREATMENT OF (INTER ALIA) CYSTIC FIBROSIS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-01-29 | — | — | US | disclosed |
| US-20150031720-A1 | ISOTHIAZOLOPYRIDINONES USEFUL FOR THE TREATMENT OF (INTER ALIA) CYSTIC FIBROSIS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-01-29 | — | — | US | disclosed |
| US-8802844-B2 | Isothiazolopyridinones useful for the treatment of (inter alia) cystic fibrosis | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-12 | — | — | US | disclosed |
| US-8802844-B2 | Isothiazolopyridinones useful for the treatment of (inter alia) cystic fibrosis | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-12 | — | — | US | disclosed |
| US-20100249180-A1 | ISOTHIAZOLOPYRIDINONES USEFUL FOR THE TREATMENT OF (INTER ALIA) CYSTIC FIBROSIS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100249180-A1 | ISOTHIAZOLOPYRIDINONES USEFUL FOR THE TREATMENT OF (INTER ALIA) CYSTIC FIBROSIS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249180-A1 | ISOTHIAZOLOPYRIDINONES USEFUL FOR THE TREATMENT OF (INTER ALIA) CYSTIC FIBROSIS | CFTR, ABCB1, ABCC8 | CSNK2A1 3268/4885PIM3 1965/4885CLK4 2325/4885 |
| US-20150031720-A1 | ISOTHIAZOLOPYRIDINONES USEFUL FOR THE TREATMENT OF (INTER ALIA) CYSTIC FIBROSIS | CFTR, ABCB1, ABCC8 | CSNK2A1 3268/4885PIM3 1965/4885CLK4 2325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.